Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Cost Effectiveness and Resource Allocation
Published in:

Open Access 01-12-2024 | Fenofibrate | Research

Cost-effectiveness of fenofibrate for preventing diabetic complications in Australia

Authors: Hansoo Kim, Juntao Lyu, Vikrama Raja, Kyoo Kim

Published in: Cost Effectiveness and Resource Allocation | Issue 1/2024

Login to get access

Abstract

Background

This study investigated the cost-effectiveness of using fenofibrate to treat type 2 diabetes in Australia. The financial burden of type 2 diabetes mellitus is estimated to surpass AUD10 billion, mainly due to the cost of diabetic complications from diabetic neuropathy. Clinical evidence from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study demonstrated that fenofibrate can reduce the risk of amputation and other diabetes-related complications.

Methods

This study used a calibrated UKPDS model with an Australian diabetes cohort to simulate complications and deaths over a 20-year time horizon. The effectiveness of fenofibrate was assessed using the FIELD study. Total cost was calculated over the 20-year time horizon. Input data was obtained from the Australian Refined-Disease Related Groups and the Australian Pharmaceutical Benefits Scheme.

Results

The model estimated that fenofibrate is associated with lower complication costs, which save over AUD 4.6 million per 1,000 patients. The most significant savings were observed in amputations. The incremental cost-effectiveness ratio for fenofibrate treatment was estimated to be AUD 739/LY gained and AUD 1189/QALY gained.

Conclusion

The use of fenofibrate in Type 2 diabetes patients is estimated to result in cost savings in an Australian setting due to fewer diabetes complications.
Literature
1.
Gray AM et al. Applied Methods of Cost-effectiveness Analysis in Health Care. Handbooks in Health Economic Evaluation Series, ed. A.M. Gray and A. Briggs. 2011, New York: Oxford University Press.
2.
Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–12.CrossRefPubMedPubMedCentral
3.
Davis WA, Knuiman MW, Davis TM. An Australian cardiovascular risk equation for type 2 diabetes: the Fremantle Diabetes Study. Intern Med J. 2010;40(4):286–92.CrossRefPubMed
4.
Lee CM, et al. The cost of diabetes in adults in Australia. Diabetes Res Clin Pract. 2013;99(3):385–90.CrossRefPubMed
5.
Schofield D et al. The costs of diabetes among Australians aged 45–64 years from 2015 to 2030: projections of lost productive life years (PLYs), lost personal income, lost taxation revenue, extra welfare payments and lost gross domestic product from Health&WealthMOD 2030. BMJ Open, 2017. 7(1): p. e013158.
6.
Magliano DJ, et al. The Productivity Burden of Diabetes at a Population Level. Diabetes Care. 2018;41(5):979–84.CrossRefPubMed
7.
Bild DE, et al. Lower-extremity amputation in people with diabetes. Epidemiology and prevention. Diabetes Care. 1989;12(1):24–31.CrossRefPubMed
8.
Nazri MY, et al. Quality of life of diabetes amputees following major and minor lower limb amputations. Med J Malaysia. 2019;74(1):25–9.PubMed
9.
Graz H, et al. Diabetes-related amputations create considerable public health burden in the UK. Diabetes Res Clin Pract. 2018;135:158–65.CrossRefPubMed
10.
11.
Rajamani K, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet. 2009;373(9677):1780–8.CrossRefPubMedPubMedCentral
12.
Audit AND. Australian National Diabetes Audit Annual Report 2022. 2023, Monash University, School of Public Health and Preventive Medicine. p. 88.
13.
Investigators FS. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–61.CrossRef
14.
Harding JL, et al. Mortality trends among people with type 1 and type 2 diabetes in Australia: 1997–2010. Diabetes Care. 2014;37(9):2579–86.CrossRefPubMed
15.
Hayes AJ, et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom prospective diabetes study: UKPDS 82. Diabetologia. 2013;56:p1925–1933.CrossRef
16.
Leal J, et al. Estimating risk factor progression equations for the UKPDS outcomes Model 2 (UKPDS 90). Diabet Med. 2021;38(10):e14656.CrossRefPubMed
17.
Glick HA et al. Economic Evaluation in Clinical Trials. Second edition ed. Handbooks in Health Economic Evaluation Series, ed. A.M. Gray and A. Briggs. 2015, New York: Oxford University Press.
18.
19.
Sibbald RG, Ayello EA. The reduction of Diabetic Foot amputations starts with preventing Foot Ulcers. Adv Skin Wound Care. 2018;31(9):389.CrossRefPubMed
20.
Armstrong DG, Wrobel J, Robbins JM. Guest Editorial: are diabetes-related wounds and amputations worse than cancer? Int Wound J. 2007;4(4):286–7.CrossRefPubMed
21.
Malik RA, Tesfaye S, Ziegler D. Medical strategies to reduce amputation in patients with type 2 diabetes. Diabet Med. 2013;30(8):893–900.CrossRefPubMed
22.
Abushanab D, et al. A systematic review of cost-effectiveness of non-statin lipid-lowering drugs for primary and Secondary Prevention of Cardiovascular Disease in patients with type 2 diabetes Mellitus. Curr Probl Cardiol. 2023;48(8):101211.CrossRefPubMed
23.
Lee L, Kim H. Exploring the evolution of Statin pricing in Australia: observations of Price Disclosure effects on Pharmaceutical benefits Scheme Expenditure. Value Health Reg Issues. 2023;40:27–34.CrossRefPubMed
24.
Davis WA, Colagiuri S, Davis TM. Comparison of the Framingham and United Kingdom prospective diabetes study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. Med J Aust. 2009;190(4):180–4.CrossRefPubMed
Metadata
Title
Cost-effectiveness of fenofibrate for preventing diabetic complications in Australia
Authors
Hansoo Kim
Juntao Lyu
Vikrama Raja
Kyoo Kim
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Cost Effectiveness and Resource Allocation / Issue 1/2024
Electronic ISSN: 1478-7547
DOI
https://doi.org/10.1186/s12962-024-00591-8

Other articles of this Issue 1/2024

Mitigating role of financial inclusion on the perceived difficulties, concerns, and borrowing for medical expenses in Saudi Arabia

  • Open Access
  • Research

Real-world effectiveness of a new powered stapling system with gripping surface technology on the intraoperative clinical and economic outcomes of gastrectomy for gastric cancer

Reimagining the relationship between economics and health– WHO ‘Health for all’ provisions

  • Open Access
  • Editorial

Out-of-pocket pharmaceutical expenditure and its determinants among Iranian households with elderly members: a double-hurdle model

  • Open Access
  • Research

Willingness to pay for cataract surgery and its associated factors in selected medical centers in Urmia, Iran

Long-term cost-utility analysis of family therapy vs. treatment as usual for young people seen after self-harm

  • Open Access
  • Research